Pipeline
JX-594
JX-963
JX-929
Clinical Trials
JX-929 was engineered from the same prototype as JX-963, targeting the epidermal growth factor (EGF)-receptor and ras signal transduction pathways. In this candidate, GM-CSF is replaced with cytosine deaminase.
